Crinetics to Present Long-Term PALSONIFY™ Data at ENDO 2025

Crinetics to Present Long-Term PALSONIFY™ Data at ENDO 2025

By, Admin 14 July 2025

Overview

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly will be presented in several oral and poster presentations at the Endocrine Society’s Annual Meeting, ENDO 2025. Notably, open-label extension (OLE) data from both the pivotal PATHFNDR-1 and PATHFNDR-2 trials will be featured in two presentations, showing the long-term clinical profile of PALSONIFY in people with acromegaly.

STatenment from Scott Struthers: Founder and Chief Executive Officer of Crinetics

With once-daily, oral PALSONIFY’s PDUFA date quickly approaching, we’re excited to see a growing body of data that continues to underscore its potential as the next generation of care for people living with acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 
“Building on the remarkable Phase 3 trial results from the PATHFNDR studies that we’ve presented at ENDO previously, the new long-term data we’re showcasing this year provide further evidence of PALSONIFY’s ability to deliver durable IGF-1 control, sustained improvements in patient symptom burden, and a consistent safety profile.”

PATHFNDR-1 Open-Label Extension (OLE) Study

  • The PATHFNDR-1 Phase 3 trial enrolled adults with acromegaly who were biochemically controlled on monthly injectable somatostatin receptor ligands (SRLs). 
  • Following a 36-week randomized, placebo-controlled period, 53 of 58 participants (91%) entered the ongoing single-arm open-label extension. 
  • An interim analysis includes data through Week 96 of total study participation (60 weeks in the OLE).
  • In patients who transitioned from injected SRLs to once-daily oral PALSONIFY, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and 0.81 ± 0.21 times the upper limit of normal (ULN) at Week 96, demonstrating durable biochemical control over this time span.
  • Growth hormone (GH) levels were also stable, with mean values of 1.0 ± 1.0 ng/mL at baseline and 1.1 ± 1.2 ng/mL at Week 96.

Symptoms measurement

Symptom control, as measured by the Acromegaly Symptom Diary (ASD)—a seven-item daily patient-reported outcome assessing core acromegaly symptoms such as headache, joint pain, sweating, fatigue, and soft tissue swelling—also remained stable at Week 96.
PALSONIFY was generally well tolerated.

Results inclusion

  • These results will be included in an oral presentation titled “Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension,” taking place July 13 from 2:45-3:00 PM PT.

PATHFNDR-2 OLE Study

  • The PATHFNDR-2 trial is a randomized, double-blind, placebo-controlled Phase 3 study evaluating once-daily oral PALSONIFY in adults with biochemically uncontrolled acromegaly (baseline IGF-1 > 1.3 × ULN). 
  • After a 24-week RC period, 103 of 106 completers (97.2%) entered the ongoing OLE, along with 11 additional patients who were eligible for the RC phase but enrolled directly into the OLE after the completion of RC phase enrollment. 
  • This interim analysis includes efficacy data from 88 patients through Week 84 (corresponding to 60 weeks in the OLE), with safety data reported for all 114 enrolled.

Sustained IGF-1 Reduction Seen with PALSONIFY at Week 84

  • Patients who had received placebo during the RC phase experienced sustained reductions in IGF-1, with a mean change from baseline of –0.81 × ULN at Week 84 (n=39). 
  • Direct-to-OLE participants (n=9) showed similar reductions (–0.75 × ULN), while those who had been treated with PALSONIFY during the RC phase (n=40) maintained control (mean change –0.01 × ULN).
  • GH, ASD symptom scores and pituitary tumor size were durably controlled over the study period.

PALSONIFY was generally well tolerated.

  • These results will be included in a poster presentation titled “Once-Daily Oral Paltusotine in the Treatment of Patients with Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension,” taking place July 14, from 12:00 PM – 1:30 PM PT. PALSONIFY Significantly Reduces Acromegaly Symptoms, ENDO 2025 Data Show
  • Additional data presented at ENDO 2025 highlighted the impact of PALSONIFY on symptom burden in acromegaly. 
  • A pooled analysis of ASD scores from PATHFNDR-1 and PATHFNDR-2 showed that greater proportions of patients treated with PALSONIFY experienced less acromegaly symptom burden compared to placebo, regardless of the magnitude of the symptom effect, treatment history, or state of biochemical disease control. 
  • In an analysis of PATHFNDR-1 data, biochemically controlled patients switching from injected SRLs to PALSONIFY saw a significant drop in day to day symptom exacerbations – from over 30% of days on SRLs to just 6.2% during stable PALSONIFY dosing (p < 0.0001). 
  • All presentations will be posted on Crinetics.com at the time of the presentation.

About PALSONIFY™ (Paltusotine) 

  • Crinetics’ lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. 
  • It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. 
  • In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). 
  • IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. 
  • Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. 

About Crinetics Pharmaceuticals 

  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. 
  • Crinetics’ lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. 
  • Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. 
  • All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!